Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19029962 | IONIZABLE CATIONIC LIPIDS | January 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 18797392 | IONIZABLE CATIONIC LIPIDS | August 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18752372 | METHOD FOR SIMPLY CONSTRUCTING TWO-COMPONENT VIRAL VECTOR AND RELATED APPLICATIONS THEREOF | June 2024 | June 2025 | Allow | 11 | 1 | 1 | No | No |
| 18602410 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | March 2024 | January 2026 | Allow | 22 | 1 | 0 | No | No |
| 18463155 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | September 2023 | January 2026 | Abandon | 28 | 1 | 0 | No | No |
| 18327728 | POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA | June 2023 | February 2026 | Allow | 33 | 1 | 0 | No | No |
| 18306673 | Tracking and Manipulating Cellular RNA via Nuclear Delivery of CRISPR/CAS9 | April 2023 | September 2025 | Abandon | 28 | 1 | 1 | No | No |
| 18191718 | COMPOSITION TO INCREASE CELLULARLONGEVITY | March 2023 | March 2025 | Abandon | 23 | 3 | 1 | No | No |
| 18112239 | METHODS FOR ANALYSIS OF SOMATIC MOBILE ELEMENTS, AND USES THEREOF | February 2023 | January 2026 | Abandon | 35 | 1 | 1 | No | No |
| 18162104 | WT1 VACCINE | January 2023 | February 2026 | Allow | 37 | 3 | 0 | No | No |
| 18000838 | NUCLEIC ACID MOLECULE TARGETING MITF GENE AND USE THEREOF | December 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 17923470 | IMPROVED COMPOSITIONS FOR CFTR MRNA THERAPY | November 2022 | December 2025 | Allow | 37 | 1 | 0 | No | No |
| 18049210 | CFTR MRNA COMPOSITIONS AND RELATED METHODS AND USES | October 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 17970170 | IMMUNOSTIMULATORY COMPOSITIONS | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17964523 | VIRAL VECTOR DOSING PROTOCOLS | October 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17938816 | In vivo targeting of Fibrosis by anti-CD5-targeted FAP-CAR T mRNA-LNP | October 2022 | August 2025 | Abandon | 34 | 5 | 1 | No | No |
| 17938008 | METHODS FOR ENGINEERING NON-NEURONAL CELLS INTO NEURONS AND USING NEWLY ENGINEERED NEURONS TO TREAT NEURODEGENERATIVE DISEASES | October 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17939707 | Immuno-Oncolytic Therapies | September 2022 | July 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 17900233 | COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA | August 2022 | September 2025 | Abandon | 36 | 2 | 0 | No | No |
| 17883973 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | August 2022 | April 2025 | Allow | 32 | 2 | 0 | No | No |
| 17759687 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | July 2022 | January 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17813984 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | July 2022 | March 2025 | Allow | 32 | 1 | 0 | No | No |
| 17813304 | MODULATING GAMMA-C-CYTOKINE ACTIVITY | July 2022 | September 2025 | Abandon | 38 | 2 | 0 | No | No |
| 17867128 | METHODS AND MEANS FOR INDUCING AN IMMUNE RESPONSE | July 2022 | February 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17859470 | DELIVERY OF GENE THERAPY TREATMENTS | July 2022 | March 2025 | Allow | 33 | 1 | 0 | No | No |
| 17859564 | THERAPEUTIC AGENTS COMPRISING ONCOLYTIC VACCINIA VIRUSES AND NK CELLS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS | July 2022 | September 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17845660 | ANELLOVIRUS COMPOSITIONS AND METHODS OF USE | June 2022 | February 2025 | Allow | 32 | 2 | 0 | No | No |
| 17749012 | TARGETED DISRUPTION OF THE T CELL RECEPTOR | May 2022 | December 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17721063 | OCULAR DELIVERY OF THERAPEUTIC AGENTS | April 2022 | September 2023 | Abandon | 17 | 1 | 1 | No | No |
| 17705803 | MESSENGER RNA VACCINES AND USES THEREOF | March 2022 | March 2025 | Allow | 36 | 1 | 0 | No | No |
| 17699035 | CORONAVIRUS VACCINE | March 2022 | September 2023 | Abandon | 18 | 2 | 0 | Yes | Yes |
| 17686245 | USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE | March 2022 | February 2026 | Abandon | 47 | 3 | 0 | Yes | No |
| 17582289 | MUTANT FACTOR VIII COMPOSITIONS AND METHODS | January 2022 | December 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17570962 | METHODS, COMPOSITIONS, AND SYSTEMS FOR DELIVERING THERAPEUTIC AND DIAGNOSTIC AGENTS INTO CELLS | January 2022 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17560197 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | December 2021 | June 2023 | Abandon | 17 | 2 | 0 | No | No |
| 17560195 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | December 2021 | December 2023 | Abandon | 24 | 2 | 0 | No | Yes |
| 17558555 | LIVER SPECIFIC DELIVERY OF MESSENGER RNA | December 2021 | April 2023 | Abandon | 16 | 2 | 0 | No | No |
| 17620331 | SYNTHETIC GENES FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA | December 2021 | December 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17553603 | RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF | December 2021 | January 2025 | Allow | 37 | 1 | 0 | No | No |
| 17547498 | BACTERIA ENGINEERED TO TREAT DISORDERS INVOLVING THE CATABOLISM OF A BRANCHED CHAIN AMINO ACID | December 2021 | August 2024 | Abandon | 32 | 0 | 1 | No | No |
| 17541018 | CD25 PRE-SELECTIVE COMBINATION ANTI-HIV VECTORS, TARGETING VECTORS, AND METHODS OF USE | December 2021 | September 2024 | Abandon | 34 | 0 | 1 | No | No |
| 17610942 | COMPOSITIONS AND METHODS FOR TARGETING MULTINUCLEATED CELLS | November 2021 | March 2026 | Abandon | 52 | 2 | 1 | Yes | No |
| 17517967 | AGENTS FOR PROMOTING TISSUE REGENERATION BY RECRUITING BONE MARROW MESENCHYMAL STEM CELLS AND/OR PLURIPOTENT STEM CELLS INTO BLOOD | November 2021 | March 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17603220 | Correction of Beta-Thalassemia Phenotype by Genetically Engineered Hematopoietic Stem Cell | October 2021 | February 2026 | Abandon | 52 | 3 | 1 | No | No |
| 17488608 | TRANSGENIC PIG ISLETS AND USES THEREOF FOR TREATING DIABETES | September 2021 | March 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17489652 | ANELLOVIRUS COMPOSITIONS AND METHODS OF USE | September 2021 | March 2022 | Allow | 6 | 1 | 0 | No | No |
| 17487562 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | September 2021 | July 2024 | Allow | 34 | 1 | 0 | No | No |
| 17438135 | OPTIMISED RAG1 DEFICIENT GENE THERAPY | September 2021 | June 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17396090 | FORMULATIONS FOR HIGHLY PURIFIED VIRAL PARTICLES | August 2021 | December 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17426613 | TREATMENT OF AGING OR AGE-RELATED DISORDERS USING XBP1 | July 2021 | June 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17382757 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | July 2021 | February 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17376135 | PROGRAMMABLE, SELF-ASSEMBLING PATCHED NANOPARTICLES, AND ASSOCIATED DEVICES, SYSTEMS AND METHODS | July 2021 | July 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17371386 | MATERIALS AND METHODS FOR TREATMENT OF HEREDITARY HAEMOCHROMATOSIS | July 2021 | August 2024 | Allow | 38 | 2 | 1 | No | No |
| 17368947 | DUAL VECTOR FOR INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS | July 2021 | September 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17347498 | TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY | June 2021 | February 2023 | Allow | 20 | 2 | 1 | Yes | No |
| 17343071 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | June 2021 | July 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17339607 | TRANSPOSITION OF NUCLEIC ACIDS INTO EUKARYOTIC GENOMES WITH A TRANSPOSASE FROM HELIOTHIS | June 2021 | May 2025 | Allow | 47 | 3 | 1 | Yes | No |
| 17325292 | TARGETED NANOPARTICLES | May 2021 | December 2025 | Abandon | 55 | 1 | 1 | No | No |
| 17321328 | METHOD OF PREPARING NUCLEASE-RESISTANT DNA-INORGANIC HYBRID NANOFLOWERS | May 2021 | February 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17294296 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SMOOTH MUSCLE DYSFUNCTION | May 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17294350 | RELAXIN RECEPTOR 1 FOR USE IN TREATMENT AND PREVENTION OF HEART FAILURE | May 2021 | August 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17244445 | METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS | April 2021 | May 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17219116 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | March 2021 | September 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17189368 | TELOMERASE REVERSE TRANSCRIPTASE-BASED THERAPIES | March 2021 | October 2025 | Abandon | 55 | 5 | 0 | No | No |
| 17189120 | CHIMERIC NUCLEIC ACID MOLECULES WITH NON-AUG TRANSLATION INITIATION SEQUENCES AND USES THEREOF | March 2021 | September 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17174505 | NEOANTIGENS EXPRESSED IN OVARIAN CANCER AND THEIR USES | February 2021 | February 2024 | Allow | 36 | 1 | 1 | No | No |
| 17170785 | PEPTIDE/LIPID-ASSOCIATED NUCLEIC ACIDS (PLANA) FOR NUCLEIC ACID DELIVERY | February 2021 | November 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17165159 | COMPOSITIONS AND METHODS FOR INDUCING SCARRING BY PERI-TUMORAL CELLS | February 2021 | July 2023 | Abandon | 30 | 0 | 1 | No | No |
| 17154309 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | January 2021 | October 2024 | Allow | 45 | 2 | 2 | No | No |
| 17142731 | LIPID NANOPARTICLE MRNA VACCINES | January 2021 | March 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17124462 | LIPID NANOPARTICLE COMPOSITIONS FOR DELIVERY OF MRNA AND LONG NUCLEIC ACIDS | December 2020 | August 2024 | Abandon | 44 | 5 | 2 | Yes | No |
| 17099140 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TET2 ENGINEERED T CELL THERAPY | November 2020 | August 2025 | Abandon | 57 | 6 | 1 | Yes | Yes |
| 17083771 | PROCESS FOR THE PREPARATION OF ERYTHROCYTES LOADED WITH ONE OR MORE SUBSTANCES OF PHARMACEUTICAL INTEREST AND SO OBTAINED ERYTHROCYTES | October 2020 | January 2025 | Allow | 51 | 2 | 1 | No | Yes |
| 17051583 | ENHANCED BCL11A RNP / CRISPR DELIVERY & EDITING USING A 3XNLS-CAS9 | October 2020 | September 2025 | Allow | 58 | 3 | 1 | No | No |
| 17050918 | HIGHLY KNOTTED MOLECULAR TOPOLOGIES FROM SINGLE-STRANDED NUCLEIC ACIDS | October 2020 | February 2025 | Allow | 52 | 2 | 1 | No | No |
| 17072611 | Membrane-Receiver Complex Therapeutics | October 2020 | July 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17067101 | METHOD OF TREATING IMMUNOTHERAPY NON-RESPONDERS WITH AN AUTOLOGOUS CELL THERAPY | October 2020 | January 2025 | Abandon | 51 | 2 | 1 | No | Yes |
| 17033166 | VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER | September 2020 | September 2024 | Allow | 47 | 4 | 0 | Yes | No |
| 17029436 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | September 2020 | January 2025 | Allow | 52 | 4 | 0 | No | No |
| 17021555 | NUCLEASE-MEDIATED REGULATION OF GENE EXPRESSION | September 2020 | November 2023 | Allow | 38 | 2 | 0 | No | No |
| 17017150 | COMPOSITIONS AND METHODS FOR TREATING MPSI | September 2020 | February 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17015995 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | September 2020 | May 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16979138 | METHODS AND COMPOSITIONS FOR USE OF TUMOR SELF-ANTIGENS IN ADOPTIVE IMMUNOTHERAPY | September 2020 | March 2025 | Allow | 54 | 3 | 1 | No | No |
| 16977385 | BIOLOGICALLY RELEVANT ORTHOGONAL CYTOKINE/RECEPTOR PAIRS | September 2020 | August 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16999459 | NEURAL STEM CELL DELIVERY OF THERAPEUTIC AGENTS | August 2020 | July 2025 | Allow | 59 | 4 | 1 | Yes | No |
| 16990356 | Compositions for In Vitro Amplification of Nucleic Acids | August 2020 | September 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16983121 | IONIZABLE CATIONIC LIPIDS | August 2020 | January 2024 | Allow | 42 | 2 | 0 | No | No |
| 16947427 | NOVEL USE OF GIT HAVING ANTI-SENESCENCE ACTIVITY | July 2020 | December 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16941148 | REGULATABLE CHIMERIC ANTIGEN RECEPTOR | July 2020 | July 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16938242 | METHODS FOR THE TREATMENT OF PROSTATE CANCER | July 2020 | September 2023 | Abandon | 38 | 2 | 0 | No | No |
| 16914567 | Targeted intracellular delivery of antiviral agents | June 2020 | December 2022 | Abandon | 30 | 1 | 0 | No | No |
| 16914422 | NANOPARTICLES INCLUDING A GLATIRAMOID USEFUL IN POLYNUCLEOTIDE DELIVERY | June 2020 | November 2022 | Abandon | 29 | 2 | 1 | Yes | No |
| 16904493 | METHODS AND COMPOSITIONS FOR IMPROVED HOMOLOGY DIRECTED REPAIR | June 2020 | November 2024 | Abandon | 53 | 3 | 1 | Yes | No |
| 16954458 | RNA-NANOSTRUCTURED DOUBLE ROBOTS AND METHODS OF USE THEREOF | June 2020 | September 2021 | Allow | 15 | 2 | 1 | No | No |
| 16772759 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING EXOSOMES-ASSOCIATED GENE EDITING | June 2020 | January 2026 | Abandon | 60 | 4 | 0 | No | Yes |
| 16770012 | MICRO- AND NANONEEDLES FOR PLANT AND OTHER CELL PENETRATION | June 2020 | May 2023 | Abandon | 36 | 2 | 2 | No | No |
| 16765632 | POLYNUCLEOTIDES ENCODING PROPIONYL-COA CARBOXYLASE ALPHA AND BETA SUBUNITS FOR THE TREATMENT OF PROPIONIC ACIDEMIA | May 2020 | January 2025 | Allow | 56 | 3 | 1 | No | No |
| 16872679 | Optically Transparent Silk Hydrogels | May 2020 | March 2024 | Allow | 46 | 2 | 0 | No | Yes |
| 16864492 | Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier | May 2020 | April 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16758824 | METHOD FOR INCREASING FETAL HEMOGLOBIN EXPRESSION LEVEL | April 2020 | April 2024 | Abandon | 48 | 3 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner POPA, ILEANA.
With a 29.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner POPA, ILEANA works in Art Unit 1633 and has examined 959 patent applications in our dataset. With an allowance rate of 18.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner POPA, ILEANA's allowance rate of 18.9% places them in the 2% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by POPA, ILEANA receive 3.26 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by POPA, ILEANA is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +21.4% benefit to allowance rate for applications examined by POPA, ILEANA. This interview benefit is in the 66% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 4.9% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 13.6% of cases where such amendments are filed. This entry rate is in the 14% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 39.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 47.8% of appeals filed. This is in the 13% percentile among all examiners. Of these withdrawals, 44.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 82.5% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 13.3% of allowed cases (in the 91% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.